
Denis Poddubnyy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4567983/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Axial spondyloarthritis. Lancet, The, 2017, 390, 73-84.	6.3	876
2	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 700.1-712.	0.5	609
3	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 2018, 77, 3-17.	0.5	484
4	Baseline radiographic damage, elevated acuteâ€phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis and Rheumatism, 2012, 64, 1388-1398.	6.7	384
5	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2016, 75, 1958-1963.	0.5	383
6	Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2011, 70, 1369-1374.	0.5	293
7	Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Annals of the Rheumatic Diseases, 2012, 71, 1616-1622.	0.5	286
8	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet, The, 2018, 392, 2441-2451.	6.3	251
9	Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Annals of the Rheumatic Diseases, 2014, 73, 817-823.	0.5	236
10	High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, 71, 572-574.	0.5	201
11	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2019, 78, 1550-1558.	0.5	171
12	Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2â€years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Annals of the Rheumatic Diseases, 2016, 75, 1438-1443.	0.5	163
13	Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteenâ€Week ResultsÂFrom a Phase <scp>III</scp> Randomized, Doubleâ€Blind, Placebo ontrolled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis and Rheumatology, 2019, 71, 599-611.	2.9	142
14	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet, The, 2020, 395, 53-64.	6.3	138
15	Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study. Annals of the Rheumatic Diseases, 2017, 76, 1502-1508.	0.5	136
16	Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis and Rheumatism, 2008, 58, 929-938.	6.7	123
17	Evaluation of 2 Screening Strategies for Early Identification of Patients with Axial Spondyloarthritis in Primary Care. Journal of Rheumatology, 2011, 38, 2452-2460.	1.0	117
18	Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology, 2019, 58, 859-868.	0.9	108

#	Article	IF	CITATIONS
19	Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Annals of the Rheumatic Diseases, 2011, 70, 1257-1263.	0.5	106
20	New evidence on the management of spondyloarthritis. Nature Reviews Rheumatology, 2016, 12, 282-295.	3.5	104
21	High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Annals of the Rheumatic Diseases, 2016, 75, 2114-2118.	0.5	103
22	Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1â€year of treatment with etanercept: results from the ESTHER trial. Annals of the Rheumatic Diseases, 2013, 72, 823-825.	0.5	100
23	Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Rheumatology, 2019, 58, 1634-1638.	0.9	100
24	Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo ontrolled Phase III Study. Arthritis and Rheumatology, 2021, 73, 110-120.	2.9	100
25	Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. Annals of the Rheumatic Diseases, 2015, 74, 1483-1487.	0.5	99
26	Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Annals of the Rheumatic Diseases, 2020, 79, 595-604.	0.5	91
27	Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. Therapeutic Advances in Musculoskeletal Disease, 2018, 10, 129-139.	1.2	86
28	Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Annals of the Rheumatic Diseases, 2012, 71, 1212-1215.	0.5	82
29	The IL-23–IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nature Reviews Rheumatology, 2019, 15, 747-757.	3.5	78
30	Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 1746-1748.	0.5	71
31	Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Annals of the Rheumatic Diseases, 2019, 78, 1545-1549.	0.5	71
32	Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Annals of the Rheumatic Diseases, 2010, 69, 1338-1341.	0.5	70
33	Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open, 2019, 5, e001005.	1.8	70
34	Improved detection of erosions in the sacroiliac joints on MRI with volumetric interpolated breath-hold examination (VIBE): results from the SIMACT study. Annals of the Rheumatic Diseases, 2018, 77, 1585-1589.	0.5	69
35	Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC). Annals of the Rheumatic Diseases, 2013, 72, 1430-1432.	0.5	67
36	Serum Adipokine Levels in Patients With Ankylosing Spondylitis and Their Relationship to Clinical Parameters and Radiographic Spinal Progression. Arthritis and Rheumatology, 2015, 67, 678-685.	2.9	67

Denis Poddubnyy

#	Article	IF	CITATIONS
37	The European Map of Axial Spondyloarthritis: Capturing the Patient Perspective—an Analysis of 2846 Patients Across 13 Countries. Current Rheumatology Reports, 2019, 21, 19.	2.1	63
38	Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 2137-2143.	0.5	62
39	The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic. Annals of the Rheumatic Diseases, 2012, 71, 1998-2001.	0.5	60
40	Similarities and differences between nonradiographic and radiographic axial spondyloarthritis. Current Opinion in Rheumatology, 2014, 26, 377-383.	2.0	58
41	Mechanism of New Bone Formation in Axial Spondyloarthritis. Current Rheumatology Reports, 2017, 19, 55.	2.1	58
42	Classification <i>vs</i> diagnostic criteria: the challenge of diagnosing axial spondyloarthritis. Rheumatology, 2020, 59, iv6-iv17.	0.9	56
43	Magnetic Resonance Imaging Compared to Conventional Radiographs for Detection of Chronic Structural Changes in Sacroiliac Joints in Axial Spondyloarthritis. Journal of Rheumatology, 2013, 40, 1557-1565.	1.0	55
44	Radiographic progression in non-radiographic axial spondyloarthritis. Expert Review of Clinical Immunology, 2018, 14, 525-533.	1.3	55
45	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatology, The, 2021, 3, e715-e723.	2.2	53
46	Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis. Rheumatology, 2020, 59, 3798-3806.	0.9	52
47	Radiographic progression in ankylosing spondylitis/axial spondyloarthritis. Current Opinion in Rheumatology, 2012, 24, 363-369.	2.0	48
48	Axial involvement in psoriatic arthritis: An update for rheumatologists. Seminars in Arthritis and Rheumatism, 2021, 51, 880-887.	1.6	48
49	Early Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 387-403.	0.8	46
50	Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care. RMD Open, 2018, 4, e000825.	1.8	45
51	Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Annals of the Rheumatic Diseases, 2018, 77, 1017-1024.	0.5	44
52	Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. Rheumatology, 2021, 60, 4778-4789.	0.9	44
53	Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Research and Therapy, 2017, 19, 240.	1.6	43
54	Course of Magnetic Resonance Imaging–Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Doubleâ€Blind, Placeboâ€Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium of Canada Methods. Arthritis and Rheumatology, 2016, 68, 418-429.	2.9	42

#	Article	IF	CITATIONS
55	Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial. Arthritis Research and Therapy, 2017, 19, 140.	1.6	40
56	Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years. Journal of Rheumatology, 2016, 43, 2142-2148.	1.0	38
57	Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS). Clinical Drug Investigation, 2020, 40, 269-278.	1.1	38
58	Choose wisely: imaging for diagnosis of axial spondyloarthritis. Annals of the Rheumatic Diseases, 2022, 81, 237-242.	0.5	38
59	Corticosteroids as risk factor for COVID-19-associated pulmonary aspergillosis in intensive care patients. Critical Care, 2022, 26, 30.	2.5	38
60	Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Rheumatology, 2018, 57, 703-711.	0.9	37
61	Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance. Arthritis Research and Therapy, 2021, 23, 106.	1.6	37
62	Axial spondyloarthritis: is there a treatment of choice?. Therapeutic Advances in Musculoskeletal Disease, 2013, 5, 45-54.	1.2	36
63	Comparison of an online self-referral tool with a physician-based referral strategy for early recognition of patients with a high probability of axial spa. Seminars in Arthritis and Rheumatism, 2020, 50, 1015-1021.	1.6	35
64	The ASAS-OMERACT core domain set for axial spondyloarthritis. Seminars in Arthritis and Rheumatism, 2021, 51, 1342-1349.	1.6	35
65	Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis—3-Year data of the ESTHER trial. Seminars in Arthritis and Rheumatism, 2016, 45, 404-410.	1.6	33
66	Uveitis in spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2095173.	1.2	32
67	Spinal radiographic progression over 2Âyears in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Arthritis Research and Therapy, 2019, 21, 142.	1.6	31
68	CT-like images of the sacroiliac joint generated from MRI using susceptibility-weighted imaging (SWI) in patients with axial spondyloarthritis. RMD Open, 2021, 7, e001656.	1.8	31
69	The risk of malignancy in patients with secukinumabâ€treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of followâ€up. British Journal of Dermatology, 2021, 185, 935-944.	1.4	30
70	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110579.	1.2	30
71	Identifying parameters associated with delayed diagnosis in axial spondyloarthritis: data from the European map of axial spondyloarthritis. Rheumatology, 2022, 61, 705-712.	0.9	29
72	Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort. Arthritis and Rheumatology, 2015, 67, 2369-2375.	2.9	28

#	Article	IF	CITATIONS
73	Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. Rheumatology, 2019, 58, 1556-1564.	0.9	28
74	Gender differences in patient journey to diagnosis and disease outcomes: results from the European Map of Axial Spondyloarthritis (EMAS). Clinical Rheumatology, 2021, 40, 2753-2761.	1.0	28
75	Consistently Good Clinical Response in Patients with Early Axial Spondyloarthritis After 3 Years of Continuous Treatment with Etanercept: Longterm Data of the ESTHER Trial. Journal of Rheumatology, 2014, 41, 2034-2040.	1.0	27
76	Impact of age, sex, and joint form on degenerative lesions of the sacroiliac joints on CT in the normal population. Scientific Reports, 2021, 11, 5903.	1.6	27
77	Joint anatomy in axial spondyloarthritis: strong associations between sacroiliac joint form variation and symptomatic disease. Rheumatology, 2021, 61, 388-393.	0.9	26
78	What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?. Rheumatology, 2018, 57, 1145-1150.	0.9	25
79	Current Unmet Needs in Spondyloarthritis. Current Rheumatology Reports, 2019, 21, 43.	2.1	24
80	Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Expert Opinion on Drug Safety, 2011, 10, 655-673.	1.0	23
81	Axial Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2020, 46, 327-341.	0.8	23
82	Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 807-818.	1.4	22
83	MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2022, 81, 1243-1251.	0.5	22
84	Therapeutic Controversies in Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 601-611.	0.8	21
85	Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Longâ€Term Anti–Tumor Necrosis Factor Treatment: Sixâ€Year Results of Continuous Treatment With Etanercept. Arthritis and Rheumatology, 2019, 71, 722-728.	2.9	21
86	IL-17 inhibition in axial spondyloarthritis: current and future perspectives. Expert Opinion on Biological Therapy, 2019, 19, 631-641.	1.4	20
87	Treatment of Axial Spondyloarthritis: What Does the Future Hold?. Current Rheumatology Reports, 2020, 22, 47.	2.1	20
88	Relation of HLA-B27, Tumor Necrosis Factor-α Promoter Gene Polymorphisms, and T Cell Cytokine Production in Ankylosing Spondylitis — A Comprehensive Genotype-Phenotype Analysis from an Observational Cohort. Journal of Rheumatology, 2011, 38, 2436-2441.	1.0	18
89	Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial. Rheumatology, 2015, 54, 257-261.	0.9	18
90	Peripheral blood mononuclear cells are hypomethylated in active rheumatoid arthritis and methylation correlates with disease activity. Rheumatology, 2021, 60, 1984-1995.	0.9	18

#	Article	IF	CITATIONS
91	Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Annals of the Rheumatic Diseases, 2021, 80, 1022-1030.	0.5	18
92	Instrument selection for the ASAS core outcome set for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2023, 82, 763-772.	0.5	18
93	Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-Inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial. BMJ Open, 2017, 7,	0.8	17
94	The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097261.	1.2	17
95	Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Research and Therapy, 2021, 23, 231.	1.6	17
96	New treatment targets in ankylosing spondylitis and other spondyloarthritides. Current Opinion in Rheumatology, 2011, 23, 346-351.	2.0	16
97	Detection of Sacroiliitis by Short-tau Inversion Recovery and T2-weighted Turbo Spin Echo Sequences: Results from the SIMACT Study. Journal of Rheumatology, 2019, 46, 376-383.	1.0	16
98	The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. Arthritis Research and Therapy, 2020, 22, 210.	1.6	16
99	Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results. Rheumatology, 2022, 61, 3299-3308.	0.9	16
100	Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial. Arthritis and Rheumatology, 2016, 68, 1899-1903.	2.9	15
101	Restless legs syndrome is a relevant comorbidity in patients with inflammatory bowel disease. International Journal of Colorectal Disease, 2018, 33, 955-962.	1.0	15
102	Emerging treatment options for spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 472-484.	1.4	15
103	Skin manifestations in spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097591.	1.2	15
104	Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study. Seminars in Arthritis and Rheumatism, 2021, 51, 766-774.	1.6	15
105	Ultra-low-dose CT detects synovitis in patients with suspected rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 31-35.	0.5	14
106	Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria. Annals of the Rheumatic Diseases, 2020, 79, 935-942.	0.5	14
107	Diagnostic delay in axial spondyloarthritis – a past or current problem?. Current Opinion in Rheumatology, 2021, 33, 307-312.	2.0	14
108	Old and new treatment targets in axial spondyloarthritis. RMD Open, 2015, 1, e000054.	1.8	13

#	Article	IF	CITATIONS
109	Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 197-210.	1.2	13
110	OP0054â€EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES. Annals of the Rheumatic Diseases, 2020, 79, 36-37.	0.5	13
111	How is early spondyloarthritis defined in the literature? Results from a systematic review. Seminars in Arthritis and Rheumatism, 2022, 55, 152032.	1.6	13
112	Decreased heart rate variability in patients with psoriatic arthritis. Clinical Rheumatology, 2012, 31, 1377-1381.	1.0	12
113	Inflammation, new bone formation and treatment options in axial spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 1439-1441.	0.5	12
114	Challenges and Advances in Targeting Remission in Axial Spondyloarthritis. Journal of Rheumatology, 2018, 45, 153-157.	1.0	12
115	Susceptibility-weighted MR imaging to improve the specificity of erosion detection: a prospective feasibility study in hand arthritis. Skeletal Radiology, 2019, 48, 721-728.	1.2	12
116	Patientâ€Reported Impact of Axial Spondyloarthritis on Working Life: Results From the European Map of Axial Spondyloarthritis Survey. Arthritis Care and Research, 2021, 73, 1826-1833.	1.5	12
117	Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity. Arthritis Research and Therapy, 2018, 20, 44.	1.6	11
118	An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus. Arthritis Research and Therapy, 2018, 20, 191.	1.6	11
119	Emerging drugs for the treatment of noninfectious uveitis. Expert Opinion on Emerging Drugs, 2019, 24, 173-190.	1.0	11
120	Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis. Joint Bone Spine, 2020, 87, 69-73.	0.8	11
121	What amount of structural damage defines sacroiliitis: a CT study. RMD Open, 2022, 8, e001939.	1.8	11
122	Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a <scp>Timeâ€Shifted</scp> Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: <scp>10â€Year</scp> Results From the German Spondyloarthritis Inception Cohort. Arthritis and Rheumatology, 2022, 74, 1515-1523.	2.9	11
123	Balancing benefits and risks in the era of biologics. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1988397.	1.2	10
124	Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: <scp>Longâ€Term</scp> Results of Two Phase <scp>III</scp> Randomized Controlled Trials. Arthritis Care and Research, 2022, 74, 759-767.	1.5	10
125	Differential diagnostic value of rheumatic symptoms in patients with Whipple's disease. Scientific Reports, 2021, 11, 5980.	1.6	10
126	Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis – a five-year update. Expert Opinion on Biological Therapy, 2013, 13, 1599-1611.	1.4	9

#	Article	IF	CITATIONS
127	Emerging drugs for the treatment of axial spondyloarthritis. Expert Opinion on Emerging Drugs, 2018, 23, 83-96.	1.0	9
128	OP0106â€SECUKINUMAB 150 MG SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM THE PHASE III PREVENT STUDY. Annals of the Rheumatic Diseases, 2020, 79, 69-70.	0.5	9
129	Baseline serum biomarkers of inflammation, bone turnover and adipokines predict spinal radiographic progression in ankylosing spondylitis patients on TNF inhibitor therapy. Seminars in Arthritis and Rheumatism, 2022, 53, 151974.	1.6	9
130	Presence of spondyloarthritis associated to higher disease activity and HLA-B27 positivity in patients with early Crohn's disease: Clinical and MRI results from a prospective inception cohort. Joint Bone Spine, 2022, 89, 105367.	0.8	9
131	Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: <scp>Threeâ€Year</scp> Results From a Phase <scp>Ilb</scp> Randomized Controlled Trial and Its <scp>Openâ€Label</scp> Extension Study. Arthritis and Rheumatology, 2022, 74, 1943-1958.	2.9	9
132	Investigation of involved tissue in axial spondyloarthritis – what have we learnt from immunohistochemical studies?. Best Practice and Research in Clinical Rheumatology, 2010, 24, 715-719.	1.4	8
133	Radiographic Evaluation of Sacroiliac Joints in Axial Spondyloarthritis — Still Worth Performing?. Journal of Rheumatology, 2017, 44, 1-3.	1.0	8
134	Precision medicine in rheumatology: are we getting closer?. Lancet, The, 2021, 397, 258-259.	6.3	8
135	Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting. Journal of Rheumatology, 2021, , jrheum.201672.	1.0	8
136	Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study. RMD Open, 2021, 7, e001769.	1.8	8
137	Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial. BMJ Open, 2021, 11, e048647.	0.8	8
138	Anatomical variation of the sacroiliac joint carries an increased risk for erosion and bone marrow oedema in axial spondyloarthritis. Rheumatology, 2023, 62, 1117-1123.	0.9	8
139	The safety of celecoxib in ankylosing spondylitis treatment. Expert Opinion on Drug Safety, 2008, 7, 401-409.	1.0	7
140	Reality of care for musculoskeletal diseases at the population level. Zeitschrift Fur Rheumatologie, 2019, 78, 73-79.	0.5	7
141	Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate. BMJ Open, 2020, 10, e039059.	0.8	7
142	Fibrinogen, factor XIII and α2-antiplasmin genotypes are associated with inflammatory activity and anti-citrullinated protein antibodies. Thrombosis Research, 2020, 191, 90-96.	0.8	7
143	Comment on â€ ⁻ Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis' by Kuwabara <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e93-e93.	0.5	7
144	Radiographic sacroiliitis progression in axial spondyloarthritis: central reading of 5 year follow-up data from the Assessment of SpondyloArthritis international Society cohort . Rheumatology, 2021, 60, 2478-2480.	0.9	7

#	Article	IF	CITATIONS
145	Diagnosing axial spondyloarthritis: estimation of the disease probability in patients with <i>a priori</i> different likelihoods of the diagnosis. Rheumatology, 2021, 60, 5098-5104.	0.9	7
146	GRAPPA 2019 Project Report. Journal of Rheumatology, 2020, 96, 53-57.	1.0	7
147	Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2022, 81, 1252-1259.	0.5	7
148	LB0001â€Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study. , 2018, , .		6
149	Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2098770.	1.2	6
150	Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210859.	1.2	6
151	Hematopoietic and mesenchymal stem cells: a promising new therapy for spondyloarthritis?. Immunotherapy, 2017, 9, 899-911.	1.0	5
152	IgA antibodies against CD74 are associated with structural damage in the axial skeleton in patients with axial spondyloarthritis. Clinical and Experimental Rheumatology, 2020, 38, 1127-1131.	0.4	5
153	CT-like images in MRI improve specificity of erosion detection in patients with hand arthritis: a diagnostic accuracy study with CT as standard of reference. RMD Open, 2022, 8, e002089.	1.8	5
154	OP0145â€Continuous Versus on Demand Treatment of Ankylosing Spondylitis with Diclofenac Over 2 Years Does not Prevent Radiographic Progression of the Spine – Results from a Randomized Prospective Multi-Center Trial (Enradas). Annals of the Rheumatic Diseases, 2015, 74, 123.2-123.	0.5	4
155	OP0256â€CHOOSE WISELY: IMAGING FOR DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 156.2-157.	0.5	4
156	What is the optimal target for a T2T approach in axial spondyloarthritis?. Annals of the Rheumatic Diseases, 2021, 80, annrheumdis-2021-220603.	0.5	4
157	Adalimumab for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2009, 5, 671-681.	1.3	3
158	Assessment of radiographic sacroiliitis in anteroposterior lumbar vs conventional pelvic radiographs in axial spondyloarthritis. Rheumatology, 2021, 60, 269-276.	0.9	3
159	Asymptomatic secondary hyperparathyroidism can mimic sacroiliitis on computed tomography. Scientific Reports, 2021, 11, 4323.	1.6	3
160	Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future?. Current Opinion in Rheumatology, 2021, 33, 363-369.	2.0	3
161	Predictive value of C-reactive protein for radiographic spinal progression in axial spondyloarthritis in dependence on genetic determinants of fibrin clot formation and fibrinolysis. RMD Open, 2021, 7, e001751.	1.8	3
162	Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to: †Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?' by van Hoeven <i>et al</i> . Annals of the Rheumatic Diseases, 2015, 74, 1-1.	0.5	3

#	Article	IF	CITATIONS
163	Contrast-enhanced CT techniques and MRI perform equally well in arthritis imaging of the hand: a prospective diagnostic accuracy study. European Radiology, 2022, 32, 6376-6383.	2.3	3
164	Correspondence on â€~No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related â€~physician-reported spondylitis'?'. Annals of the Rheumatic Diseases, 2023, 82, e187-e187.	0.5	3
165	THU0071â€Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Demonstrate the Same Clinical Disease Course over Two Years: Results from the GESPIC Cohort. Annals of the Rheumatic Diseases, 2014, 73, 201.1-201.	0.5	2
166	Etanercept for the treatment of non-radiographic axial spondyloarthritis. Expert Review of Clinical Immunology, 2016, 12, 493-500.	1.3	2
167	Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis. Arthritis Research and Therapy, 2019, 21, 126.	1.6	2
168	OP0048â€DIAGNOSING AXIAL SPONDYLOARTHRITIS: ESTIMATION OF THE DISEASE PROBABILITY IN PATIENTS WITH A PRIORI DIFFERENT LIKELIHOODS OF THE DIAGNOSIS. Annals of the Rheumatic Diseases, 2021, 80, 25-26.	0.5	2
169	POS0226â€BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY. Annals of the Rheumatic Diseases, 2021, 80, 332-333.	0.5	2
170	Detection of radiographic sacroiliitis with an artificial neural network in patients with suspicion of axial spondyloarthritis. Rheumatology, 2021, 60, 5868-5869.	0.9	2
171	Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110514.	1.2	2
172	Fractal analysis of perfusion imaging in synovitis: a novel imaging biomarker for grading inflammatory activity based on assessing angiogenesis. RMD Open, 2022, 8, e002078.	1.8	2
173	A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs. Clinical and Experimental Rheumatology, 2009, 27, S148-51.	0.4	2
174	THU0273â€Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after one year of treatment with etanercept - results of the esther trial:. Annals of the Rheumatic Diseases, 2013, 71, 247.2-247.	0.5	1
175	OP0097â€Cigarette smoking predicts radiographic progression in the spine in patients with axial spondyloarthritis in a dose-dependent manner. Annals of the Rheumatic Diseases, 2013, 71, 85.3-86.	0.5	1
176	SAT0245â€Elevated serum levels of sclerostin and periostin protect against syndesmophyte formation in patients with ankylosing spondylitis and high activity of systemic inflammation. Annals of the Rheumatic Diseases, 2013, 71, 554.3-554.	0.5	1
177	OP0091â€Prediction of radiographic spinal progression using biomarkers in patients with ankylosing spondylitis who are at high risk for progression:. Annals of the Rheumatic Diseases, 2013, 71, 83.3-84.	0.5	1
178	FRI0114â€Reaching A Status of Low Disease Activity Spontaneously over Two Year Follow-Up in Active Patients with Non-Radiographic Axial Spondyloarthritis in Comparison to Ankylosing Spondylitis not Treated with TNF Blockers. Annals of the Rheumatic Diseases, 2014, 73, 422.3-423.	0.5	1
179	Golimumab for treatment of axial spondyloarthritis. Immunotherapy, 2016, 8, 107-115.	1.0	1
180	SAT0395â€Similarities and differences between non-radiographic and radiographic axial spondyloarthritis in proof cohort. , 2017, , .		1

Denis Poddubnyy

#	Article	IF	CITATIONS
181	Should we combine biologics with methotrexate in axial spondyloarthritis?. Autoimmunity Reviews, 2019, 18, 102402.	2.5	1
182	Response to: â€~Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?' by Wallman et al. Annals of the Rheumatic Diseases, 2019, , annrheumdis-2019-216735.	0.5	1
183	Relation of α2-Antiplasmin Genotype and Genetic Determinants of Fibrinogen Synthesis and Fibrin Clot Formation with Vascular Endothelial Growth Factor Level in Axial Spondyloarthritis. International Journal of Molecular Sciences, 2020, 21, 9383.	1.8	1
184	POS0453â€VALIDATION OF THE SIMPLIFIED DISEASE ACTIVITY INDEX (SDAI) WITH A QUICK QUANTITATIVE C-REACTIVE PROTEIN ASSAY (SDAI-Q) IN PATIENTS WITH RHEUMATOID ARTHRITIS: A NATIONAL, MULTICENTER STUDY. Annals of the Rheumatic Diseases, 2021, 80, 456.2-457.	0.5	1
185	POS0969â€UNVEILING AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS: AN ANCILLARY ANALYSIS OF THE ASAS-perSpA STUDY. Annals of the Rheumatic Diseases, 2021, 80, 750-751.	0.5	1
186	FRI0170â€Consensus definitions for mri lesions in the sacroiliac joints of patients with axial spondyloarthritis: first analysis from the assessments in spondyloarthritis international society (ASAS) classification cohort. , 2018, , .		1
187	THU0230â€Performance of an online self-referral questionnaire compared to a physician-based referral approach to identify patients with a high probability of axial spondyloarthritis: results from the optiref study. , 2018, , .		1
188	THU0276â€Mri lesion definitions in axial spondyloarthritis: a consensus reappraisal from the assessments in spondyloarthritis international society (ASAS). , 2018, , .		1
189	OP0249â€The contribution of structural mri lesions to detection of sacroiliitis in patients in the assessments in spondyloarthritis international society (ASAS) classification cohort. , 2018, , .		1
190	The impact of psoriasis on the clinical characteristics, disease burden and treatment patterns of peripheral spondyloarthritis. Rheumatology, 2022, 62, 135-146.	0.9	1
191	OA35â€∫Efficacy of secukinumab and HLA-B27 subtypes: results from a Phase 3b randomised controlled trial in axial SpA. Rheumatology, 2022, 61, .	0.9	1
192	Improving diagnosis of ankylosing spondylitis and spondyloarthritis in general. International Journal of Clinical Rheumatology, 2011, 6, 655-667.	0.3	0
193	THU0358â€Constant Clinical Response in Patients with Early Axial Spondyloarthritis after Continuous Treatment with Etanercept - 4 Year Data of the Esther Trial. Annals of the Rheumatic Diseases, 2013, 72, A286.1-A286.	0.5	0
194	FRI0282â€Insights into progression of structural damage of sacroiliac joints in patients with axial spondyloarthritis: Introduction of new scoring system for radiographic sacroiliitis:. Annals of the Rheumatic Diseases, 2013, 71, 409.2-409.	0.5	0
195	SAT0255â€Predictive and protective role of adipokines in radiographic spinal progression in patients with ankylosing spondylitis:. Annals of the Rheumatic Diseases, 2013, 71, 558.1-558.	0.5	0
196	SAT0265â€Ratio of non-radiographic and radiographic axial spondyloarthritis in patients referred because of back pain is dependent on symptom duration. Annals of the Rheumatic Diseases, 2013, 71, 561.2-561.	0.5	0
197	OP0247â€Reduction of radiographic spinal progression in patients with ankylosing spondylitis treated with non-steroidal anti-inflammatory drugs is most evident in the presence of syndesmophytes and active systemic inflammation. Annals of the Rheumatic Diseases, 2013, 71, 139.1-139.	0.5	0
198	THU0263â€Development of chronic inflammatory changes on whole body magnetic resonance imaging in patients with early axial spondyloarthritis after two years of continuous treatment with etanercept – 2 year data of the esther trial:. Annals of the Rheumatic Diseases, 2013, 71, 243.3-244.	0.5	0

#	Article	IF	CITATIONS
199	FRIO423â€Effective prevention of new inflammatory bony lesions on magnetic resonance imaging in patients with early axial spondyloarthritis during treatment with etanercept over 2 years - data of the esther trial. Annals of the Rheumatic Diseases, 2013, 72, A517.2-A518.	0.5	0
200	FRI0113â€Persistently High Disease Activity According to the ASDAS is Associated with Accelerated Radiographic Spinal Progression in Patients with Axial Spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 422.2-422.	0.5	0
201	SAT0371â€Ustekinumab Treatment in Ankylosing Spondylits (AS) Patients Does not Modulate Effector CD4+ T Cell Frequencies Including TH17 Cells. Annals of the Rheumatic Diseases, 2014, 73, 727.3-728.	0.5	0
202	OP0155â€Ustekinumab Effectively Reduces Active Inflammation as Detected by Magnetic Resonance Imaging in Patients with Active Ankylosing Spondylitis: Results of A 28-Week, Prospective, Open-Label, Proof-Of-Concept Study (TOPAS). Annals of the Rheumatic Diseases, 2014, 73, 120.1-120.	0.5	0
203	AB0664â€Efficacy and Safety of Methylprednisolone Administered Intravenously for the Treatment of Patients with Active Ankylosing Spondylitis: Results of A 12-Week, Prospective, Open-Label Study (METALL): Table 1 Annals of the Rheumatic Diseases, 2014, 73, 1024.3-1025.	0.5	0
204	THU0194â€Serum Biomarkers Associated with Disease Activity and Response to Ustekinumab in Patients with Ankylosing Spondylitis in the Topas Study. Annals of the Rheumatic Diseases, 2015, 74, 265.1-265.	0.5	0
205	THU0200â€Sustained and Similar Clinical Response to Etanercept After 6 Years of Treatment in Patients with Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Long-term Results of the Esther Trial. Annals of the Rheumatic Diseases, 2015, 74, 267.2-268.	0.5	0
206	OP0172â€No Differences in the Rate of New Fatty Lesions Following Resolution of Inflammation on MRI Between Infliximab Added to Naproxen and Naproxen Alone in Early Axial Spondyloarthritis: Results from the Part I of the Infast Study. Annals of the Rheumatic Diseases, 2015, 74, 135.1-135.	0.5	0
207	SAT0240â€New Inflammatory Lesions in Axial Spondyloarthritis are More Likely to Occur in the Areas Already Affected by Inflammation in the Past. Annals of the Rheumatic Diseases, 2015, 74, 745.2-745.	0.5	0
208	Blocking Interleukin-12 and Interleukin-23 in the Treatment of Axial Spondyloarthritis. Current Treatment Options in Rheumatology, 2015, 1, 231-238.	0.6	0
209	THU0407â€Baseline Results from Proof – A 5-Year Observational Study of Long-Term Disease Outcome in Axial Spondyloarthritis. Annals of the Rheumatic Diseases, 2016, 75, 335.3-336.	0.5	0
210	THU0379â€Clinical Disease Activity Measures Are Associated with Radiographic Spinal Progression in Early Axial Spondyloarthritis. Annals of the Rheumatic Diseases, 2016, 75, 324.2-325.	0.5	0
211	OP0080â€Higher Serum Level of Leptin Might Be Responsible for Less Structural Damage in The Spine in Female Patients with Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 2016, 75, 84.3-85.	0.5	0
212	SAT0422â€Long-Term anti-TNF Treatment Is Associated with Reduction of Progression of Radiographic Changes in The Sacroiliac Joints in Patients with Non-Radiographic Axial SpA: Six-Year Results of The Esther Trial. Annals of the Rheumatic Diseases, 2016, 75, 823.2-824.	0.5	0
213	Chronic meningococcaemia—a medical oxymoron. Rheumatology, 2017, 56, 1819-1821.	0.9	0
214	FRIO435â€Comparison between central and local assessment of radiographic sacroiliitis in patients with recently diagnosed axial spondyloarthritis in proof study. , 2017, , .		0
215	OP0118â€Impact of radiographic damage in the sacroiliac joints on function and spinal mobility in patients with axial spondyloarthritis: results from the german spondyloarthritis inception cohort. , 2017, , .		0
216	Recent advances in spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 329-330.	1.4	0

#	Article	IF	CITATIONS
217	FRI0173â€Identification of a typical pattern of mri lesions of sacroiliac joints in patients with osteitis condensans ilii as compared to axial spondyloarthritis. , 2018, , .		0
218	FRI0191â€Similarities and differences between osteitis condensans ilii and axial spondyloarthritis patients presenting with chronic back pain in a rheumatology setting. , 2018, , .		0
219	OP0025â€Identification of predictors of structural damage progression in the sacroiliac joints in patients with early axial spondyloarthritis on a long-term anti-tnf treatment. , 2018, , .		0
220	AB0859â€Similarities and differences between non-radiographic and radiographic axial spondyloarthritis in proof china cohort. , 2018, , .		0
221	Response to †Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier' by Alunno <i>et al</i> . Annals of the Rheumatic Diseases, 2019, 78, e55-e55.	0.5	0
222	Pharmacologic Nonbiologic Treatment of Axial Spondyloarthritis. , 2019, , 217-226.		0
223	HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort. Genes and Immunity, 2019, 20, 671-677.	2.2	0
224	FRI0636â€SUSCEPTIBILITY WEIGHTED SEQUENCES IN MAGNETIC RESONANCE IMAGINGCAN CREATE COMPUT TOMOGRAPHY-LIKE IMAGES AND IMPROVE THE ACCURACY OF STRUCTURAL LESION DETECTION OF THE SACROILIAC JOINT IN AXIAL SPONDYLOARTHRITIS. , 2019, , .	ED	0
225	SAT0346â€EARLY RECOGNITION OF AXIAL SPONDYLOARTHRITIS IN PATIENTS WITH ACUTE ANTERIOR UVEITIS: COMPARISON OF TWO REFERRAL STRATEGIES. , 2019, , .		0
226	THU0366â€MAGNETIC RESONANCE IMAGING IN COMPARISON WITH CONVENTIONAL RADIOGRAPHY FOR DETECTION OF STRUCTURAL CHANGES TYPICAL FOR SPA – DATA FROM THE ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) COHORT. , 2019, , .		0
227	POS0923â€INFLUENCE OF BASELINE DEMOGRAPHICS ON IMPROVEMENTS IN DISEASE ACTIVITY MEASURES IN PATIENTS WITH ANKYLOSING SPONDYLITIS RECEIVING UPADACITINIB: A POST HOC SUBGROUP ANALYSIS OF SELECT-AXIS 1. Annals of the Rheumatic Diseases, 2021, 80, 722.2-723.	0.5	0
228	POS1002â€BASELINE CALPROTECTIN AND VISFATIN LEVELS PREDICT RADIOGRAPHIC SPINAL PROGRESSION AFTER 2 YEARS IN ANKYLOSING SPONDYLITIS PATIENTS ON TNF INHIBITOR THERAPY. Annals of the Rheumatic Diseases, 2021, 80, 769.2-770.	0.5	0
229	OP0139â€A TIME-SHIFTED EFFECT OF TUMOR NECROSIS FACTOR INHIBITORS ON RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: LONG-TERM RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT. Annals of the Rheumatic Diseases, 2021, 80, 81-82.	0.5	0
230	OP0031â€SHARED AND DISTINCT GUT MICROBIOME SIGNATURES IN PATIENTS WITH AXIAL SPONDYLOARTHR AND ITS RELATED IMMUNE-MEDIATED DISEASES. Annals of the Rheumatic Diseases, 2021, 80, 17.1-17.	ITIS 0.5	0
231	POS1007â€OPTIMIZING A REFERRAL STRATEGY FOR PATIENTS WITH A HIGH PROBABILITY OF AXIAL SPONDYLOARTHRITIS: THE ROLE OF AGE AND SYMPTOM DURATION. Annals of the Rheumatic Diseases, 2021, 80, 771.3-772.	0.5	0
232	POS0244â€PATIENT JOURNEY WITH AXIAL SPONDYLOARTHRITIS: CRITICAL ISSUES FROM THE PATIENT PERSPECTIVE. RESULTS FROM THE EUROPEAN MAP OF AXIAL SPONDYLOARTHRITIS (EMAS). Annals of the Rheumatic Diseases, 2021, 80, 343.2-344.	0.5	0
233	POS0065-PAREâ€HEALTH IMPACT OF OVERWEIGHT AND OBESITY IN PATIENTS WITH AXIAL SPONDYLOARTHRI RESULTS FROM THE EUROPEAN MAP OF AXIAL SPONDYLOARTHRITIS (EMAS). Annals of the Rheumatic Diseases, 2021, 80, 239.2-239.	TIS. 0.5	0
234	POS0990â€FACTORS ASSOCIATED WITH ENGAGING IN PHYSICAL ACTIVITY IN AXIAL SPONDYLOARTHRITIS. RESULTS FROM THE EUROPEAN MAP OF AXIAL SPONDYLOARTHRITIS (EMAS). Annals of the Rheumatic Diseases, 2021, 80, 763.1-763.	0.5	0

#	Article	IF	CITATIONS
235	FRI0169â€Elevated LBP Levels and in Vivo Activation of Monocytes as Potential Indicators of Bacterial Translocation in Axial Spondyloarthritis: Table 1 Annals of the Rheumatic Diseases, 2014, 73, 443.1-443.	0.5	О
236	THU0199â€Functional Status Remains Stable Despite Continuous Radiographic Spinal Progression Over Ten Years in Patients with Ankylosing Spondylitis Receiving Anti-TNF Therapy. Annals of the Rheumatic Diseases, 2015, 74, 267.1-267.	0.5	0
237	FRIO397â€The Diagnostic Value of The Symptom of Inflammatory Back Pain in Axial Spondyloarthritis in The Rheumatology Setting. Annals of the Rheumatic Diseases, 2016, 75, 578.3-579.	0.5	Ο
238	THU0251â€Characteristics of newly diagnosed axial spondyloarthritis patients in rheumatology practices across germany. , 2018, , .		0
239	FRIO2O7â€The incorporation of the antero-posterior lumbar spine view in the modified stoke ankylosing spondylitis spine scoreonly marginally improves detection of radiographic spinal progression in axial spondyloarthritis. , 2018, , .		0
240	FRI0169â€First validation of consensus definitions for mri lesions in the sacroiliac joint by the assessments in spondyloarthritis international society (ASAS) mri group. , 2018, , .		0
241	THU0274â€Assessment of radiographic sacroiliitis on antero-posterior lumbar radiographs as compared to conventional pelvic radiographs in patients with axial spondyloarthritis. , 2018, , .		Ο
242	SP0122â€Tapering in axial spondyloarthritis – to do or not to do?. , 2018, , .		0
243	FRI0198â€Which factors influence psychological well-being of patients with axial spondyloarthritis? – data from a cross-sectional survey linked to insurance claims. , 2018, , .		О
244	FRI0194â€Ankylosing spondylitis disease activity score (ASDAS) based on a quick quantitative crp assay performs similarly well to asdas based on conventional crp in patients with axial spondyloarthritis. , 2018, , .		0
245	FRI0175â€Rates and predictors of radiographic sacroiliitis progression after central reading in patients with axial spondyloarthritis from the asas cohort: a 5-year follow-up study. , 2018, , .		0
246	FRI0154â€Added value of biomarkers compared to routine clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. , 2018, , .		0
247	SAT0287â€What are the economic implications of anti-tnf therapy in patients with axial spondyloarthritis? – results of a health insurance claims data analysis. , 2018, , .		Ο
248	Ultra-Low-Dose Computed Tomography Subtraction for the Detection of Synovitis in Patients with Inflammatory Joint Disease. Seminars in Musculoskeletal Radiology, 2019, 23, .	0.4	0
249	Controversies in rheumatology: imaging of enthesitis in spondyloarthritis—does it mean anything for treatment decisions?. Rheumatology, 2022, , .	0.9	Ο